AGEPHA Pharma’s LODOCO gets US FDA approval for cardiovascular disease
Pharmaceutical Technology
JUNE 21, 2023
Participants treated with LODOCO had a 31% reduction in the overall risk of cardiovascular death, spontaneous myocardial infarction or ischaemic stroke when added to statins and other cardiology prevention therapies, compared to those treated with placebo.
Let's personalize your content